Ai In Biomarker Discovery Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

AI in biomarker discovery encompasses software platforms, algorithms, and services that analyze complex biological datasets to identify novel biomarkers for diseases, drug targets, and patient stratification. The technology spans multiple omics disciplines including genomics, proteomics, metabolomics, and bioinformatics, enabling researchers to process vast datasets far more efficiently than traditional methods. The broader biomarker discovery market, which includes non-AI methods, was valued at approximately $22.31 billion in 2025 with a 12.7% CAGR through 2034, while the AI-specific segment is experiencing significantly higher growth due to its transformative potential.

The primary engine of market expansion is the exponential growth of biological data from next-generation sequencing, high-throughput screening, and multi-omics studies, which requires AI tools to analyze effectively. Pharmaceutical companies face mounting pressure to reduce drug development timelines and costs, with AI-driven biomarker identification offering the potential to streamline clinical trials and improve success rates. Rising prevalence of chronic diseases like cancer, neurological disorders, and cardiovascular conditions has intensified demand for better diagnostic tools and targeted therapies that biomarkers enable.

The market is segmented by component into software platforms, hardware infrastructure, and professional services, with software representing the largest share as it delivers the core analytical capabilities. Application-wise, oncology dominates biomarker discovery efforts, followed by neurology, cardiology, and immunology, reflecting the areas of greatest unmet medical need and research investment. North America leads regional adoption due to strong pharmaceutical R&D spending, advanced IT infrastructure, and favorable regulatory environments, while Europe and the Asia-Pacific region are growing rapidly as biotech hubs expand in the UK, Germany, China, and Japan.

What are the recent trends and outlook?

Integration of multi-modal AI combining imaging, genomic, clinical, and real-world evidence data is becoming the next frontier, enabling more comprehensive biomarker panels that capture disease complexity better than single-modality approaches. Partnerships between AI platform companies and major pharmaceutical firms are accelerating as drugmakers seek external innovation, with collaboration deals increasingly structured around specific disease targets or therapeutic modalities. Over the forecast period through 2031, the market is expected to continue its rapid expansion as regulatory pathways for AI-derived biomarkers mature and as the technology demonstrates tangible impact on drug development success rates and patient outcomes.

Named companies and quantified developments shaping the Ai In Biomarker Discovery Market market.

• •Sanofi - In October 2024, Sanofi collaborated with SandboxAQ to locate biomarkers using large quantitative models (LQMs) to gain a better understanding of human biology.
• •Hanmi Pharmaceutical - In October 2024, Hanmi Pharmaceutical collaborated with MEDiC Life Sciences to use MEDiC’s MCAT platform to identify cancer biomarkers for one of Hanmi’s clinical assets.
• •Alzheimer’s Drug Discovery Foundation (ADDF) - In August 2024, the Alzheimer’s Drug Discovery Foundation (ADDF) invested $3.2 million in the University of Nevada, Las Vegas, to develop a biomarker observatory to diagnose and monitor Alzheimer’s disease.
• •Towards Healthcare - The biomarkers market size is projected to grow to US$ 419.89 billion by 2035, rising at a CAGR of 14.54% from 2026 to 2035.
• •Nova One Advisor - By end-user, the pharmaceutical and biotechnology companies segment held a dominant position in the drug discovery technology market with a share of 55% in 2025.